Draupnir Bio raises €12.0M Seed round

17 July 2024· Copenhagen, Denmark· health, drug_discovery, biotech, b2b, deep_hardware

The proceeds will be used to advance the company's preclinical pipeline of oral, small molecule protein degraders targeting inflammatory and neurological disorders.

Investors

LeadMP Healthcare

Also participating

Gilde HealthcareNovo HoldingsEIFOINKEF Capital

About Draupnir Bio

Stage

Seed

Headquarters

Copenhagen, Denmark

Founded

2017

Team Size

6–20

Sectors

healthdrug_discoverybiotechb2bdeep_hardware

https://draupnir.bio/

Source: https://www.globenewswire.com/news-release/2024/07/17/2914443/0/en/Draupnir-Bio-completes-12-million-seed-round-to-progress-development-of-oral-small-molecule-degraders-of-extracellular-proteins.html